Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · IEX Real-Time Price · USD
84.79
-0.06 (-0.07%)
At close: Jul 2, 2024, 4:00 PM
83.14
-1.65 (-1.95%)
After-hours: Jul 2, 2024, 4:03 PM EDT
Ligand Pharmaceuticals Employees
Ligand Pharmaceuticals had 58 employees as of December 31, 2023. The number of employees decreased by 18 or -23.68% compared to the previous year.
Employees
58
Change (1Y)
-18
Growth (1Y)
-23.68%
Revenue / Employee
$2,039,879
Profits / Employee
$1,661,103
Market Cap
1.52B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 58 | -18 | -23.68% |
Dec 31, 2022 | 76 | -78 | -50.65% |
Dec 31, 2021 | 154 | -1 | -0.65% |
Dec 31, 2020 | 155 | 40 | 34.78% |
Dec 31, 2019 | 115 | -1 | -0.86% |
Dec 31, 2018 | 116 | 77 | 197.44% |
Dec 31, 2017 | 39 | 17 | 77.27% |
Dec 31, 2016 | 22 | 1 | 4.76% |
Dec 31, 2015 | 21 | 2 | 10.53% |
Dec 31, 2014 | 19 | -1 | -5.00% |
Dec 31, 2013 | 20 | -1 | -4.76% |
Dec 31, 2012 | 21 | 0 | - |
Dec 31, 2011 | 21 | -10 | -32.26% |
Dec 31, 2010 | 31 | -41 | -56.94% |
Dec 31, 2009 | 72 | -24 | -25.00% |
Dec 31, 2008 | 96 | 37 | 62.71% |
Dec 31, 2007 | 59 | -63 | -51.64% |
Dec 31, 2006 | 122 | -371 | -75.25% |
Dec 31, 2005 | 493 | -26 | -5.01% |
Dec 31, 2004 | 519 | 58 | 12.58% |
Dec 31, 2003 | 461 | 59 | 14.68% |
Dec 31, 2002 | 402 | 51 | 14.53% |
Dec 31, 2001 | 351 | -5 | -1.40% |
Dec 31, 2000 | 356 | -29 | -7.53% |
Dec 31, 1999 | 385 | -33 | -7.89% |
Dec 31, 1998 | 418 | 73 | 21.16% |
Dec 31, 1997 | 345 | 16 | 4.86% |
Dec 31, 1996 | 329 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Alignment Healthcare | 1,536 |
Alphatec Holdings | 839 |
Supernus Pharmaceuticals | 652 |
InMode | 581 |
Dynavax Technologies | 408 |
Mirum Pharmaceuticals | 264 |
Kura Oncology | 142 |
Neumora Therapeutics | 124 |
LGND News
- 5 days ago - Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years - Business Wire
- 14 days ago - Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults - Business Wire
- 5 weeks ago - Ligand to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Ligand Reports First Quarter 2024 Financial Results - Business Wire
- 2 months ago - Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement - Business Wire
- 2 months ago - Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 - Business Wire
- 3 months ago - Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference - Business Wire
- 3 months ago - Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™ - Business Wire